GTx 758

Drug Profile

GTx 758

Alternative Names: Capesaris; GTx-758

Latest Information Update: 25 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GTx
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Selective estrogen receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Prostate cancer

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 06 May 2016 Efficacy and pharmacodynamics data from a phase II trial in Prostate cancer presented at the 111th Annual Meeting of the American Urological Association (AUA - 2016)
  • 21 Jul 2015 Phase-II development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top